Loading clinical trials...
Loading clinical trials...
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Conditions
Interventions
Mavodelpar
Placebo
Locations
41
United States
University of California, San Diego
La Jolla, California, United States
Myology Institute, University of Florida
Gainesville, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Columbia University Irving Medical Center
New York, New York, United States
Akron Children's Hospital
Akron, Ohio, United States
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Start Date
May 21, 2021
Primary Completion Date
September 12, 2023
Completion Date
October 5, 2023
Last Updated
May 8, 2024
Lead Sponsor
Reneo Pharma Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions